Assessing the Safety of Endoscopic Sinus Surgery After COVID‐19 Infection Authors: Ella Prebel Jackert, Oluwatobiloba Ayo‐Ajibola, Eric X Wei Published: 2025 ABSTRACT ABSTRACTObjectiveThis study seeks to characterize the impact of COVID‐19 infection on endoscopic sinus surgery (ESS) outcomes.MethodsThe TriNetX database identified patients with chronic rhinosinusitis who underwent ESS from January 1, 2020 to December 31, 2024. Cohorts included patients who had a diagnosis of COVID‐19 infection within 2 months before ESS (recent infection), and those who did not. A cohort of those with COVID‐19 infection between 2 months and 1 year before ESS (distant infection), was compared to a control without recent or distant infection. Propensity score matching (PSM) controlled for demographics and comorbid conditions. Relative risks (RRs) were calculated to determine risks for postoperative complications and healthcare utilization.ResultsA total of 49,609 patients underwent ESS during the study period. After PSM, there were 10,803 patients with and without recent COVID‐19 infection, and 3804 patients with or without distant COVID‐19 infection. Recent COVID‐19 infection increased the risk of epistaxis [RR: 1.236, 95% CI: (1.036, 1.474)], and nasal congestion [RR: 1.273, 95% CI: (1.016, 1.596)] within 2 months of ESS. There was no difference in risk for major complications identified between any cohort.ConclusionRecent COVID‐19 infection may increase the risk of post‐operative epistaxis, but not major complications, highlighting the overall safety of ESS after recent COVID‐19 infection and the importance of considering the timing of COVID‐19 infection when evaluating surgical risk and postoperative care needs for ESS patients.Level of EvidenceLevel III.Keywords: chronic rhinosinusitis, COVID‐19, endoscopic sinus surgery Introduction The COVID‐19 pandemic, due to the SARS‐CoV‐2 virus, has led to wide‐scale changes in the care of surgical patients. During the peak of the COVID‐19 pandemic in 2020, an estimated 20 million elective surgeries were canceled or postponed globally [1], causing significant disruption for patients and healthcare systems. Despite many healthcare systems returning to their prior functioning capacity, vestiges of this period remain, as evidence‐based guidelines regarding the optimal timing for surgery in patients recovering from COVID‐19 remain unclear [2]. Prior studies from 2020 to 2022 displayed a heightened risk of postoperative respiratory complications and mortality among patients undergoing elective or emergency surgery within 6–8 weeks of infection [3, 4, 5], supporting calls for delays in surgical timing [3, 6]. However, a more recent study from 2023 demonstrated no increased risk of postoperative complications associated with COVID‐19 infection within 60 days of surgery, with others suggesting risk is decreased with COVID‐19 vaccination [7, 8]. The impact of recent COVID‐19 infection on the safety of outpatient or elective surgical procedures, particularly surgeries of the nasal cavity and paranasal sinuses, is not well characterized. Given the pathophysiology of COVID‐19 upper respiratory tract infections [9], it is essential to better understand the effect recent infection may have on the safety of sinus surgery. Endoscopic sinus surgery (ESS) is a minimally invasive surgical procedure widely utilized as management for chronic rhinosinusitis (CRS), and is highly efficacious in reducing recurrence and improving patient health‐related quality of life [10, 11, 12, 13]. As the symptoms of CRS, such as nasal congestion and anosmia, often overlap with those of COVID‐19 infection, it is likely the pathologies may have synergistic effects on nasal mucosal inflammation [14, 15, 16, 17]. Our recent study investigating the safety of septorhinoplasty and inferior turbinate reduction in the context of recent COVID‐19 infection found recent infection did not increase the risk for major or minor surgical complications, supporting the safety of nasal surgery in recently recovered patients [18]. Given the risk of worsened sinus symptoms in CRS patients recovering from COVID‐19 infection, determining the safety of ESS in patients with recent COVID‐19 is essential. Our study aims to determine the risk of postoperative ESS complications in CRS patients with recent COVID‐19 infection. These findings may help guide clinicians in determining optimal surgical timing in CRS patients and counseling patients about the risks and benefits. Materials and Methods Data from TriNetX does not involve human subject intervention or interaction and is de‐identified and compliant with HIPAA Privacy Rules Section §164.514(a). This research was thus exempt from Institutional Review Board (IRB) review. Data analysis was conducted on May 19, 2025. Study Population This is a retrospective cohort study utilizing the TriNetX US Collaborative Network, a globally federated health research network with access to de‐identified patient electronic medical records from 64 health care organizations. International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10) codes and Current Procedural Terminology (CPT) codes were utilized to identify patients for the study and investigate their postoperative outcomes. Adult patients (18 years +) with CRS (ICD‐10: all J32 codes) who underwent ESS (CPT 31254, −55, −56, −67, −76, −87, −88) [19] from January 1, 2020 to December 31, 2024 were identified. Patients with a history of emergent or urgent indications for ESS—intracranial abscess, fungal infection, cavernous or sagittal sinus thrombosis, meningitis, orbital cellulitis, and subperiosteal abscess—were excluded. Cohorts were stratified based on binary incidence of COVID‐19 diagnosis infection by ICD‐10 code (ICD‐10 U07.1), viral polymerase chain reaction laboratory test or rapid‐testing (see Table S1 for laboratory codes used) within 2 months before ESS (recent infection). Additionally, cohorts were created including patients who had COVID‐19 infection between 2 months and 1 year before ESS (distant infection), and those who did not have recent or distant infection. Outcomes of Interest The primary outcomes of interest were minor and major postoperative complications. Minor postoperative complications included abscess, epistaxis, orbital hematoma, surgical infection, anosmia, nasal congestion, and ecchymosis. Major postoperative complications included orbital injury, cerebrospinal fluid (CSF) leak, pneumonia, ventilator dependence, deep vein thrombosis, pulmonary embolism, stroke, acute myocardial infarction (MI), sepsis, other venous thromboembolism (VTE), and death. Secondary outcomes included post‐ESS inpatient hospitalization and rates of operative intervention and emergency department visits for patients with postoperative epistaxis (CPT: 30901‐6, 30920, 31241). Patients with outcomes present prior to ESS were excluded from the analysis. A description of the ICD‐10 and CPT codes used for queries and analysis is included in Tables S1 and S2. Statistical Analysis Baseline demographic characteristics of all cohorts studied were collected, including age at time of ESS (index event), sex, race, and ethnicity. Prevalence of comorbid conditions including diabetes, chronic obstructive pulmonary disease (COPD), obesity, hypertension, and smoking was also collected for all cohorts (see Table S1 for ICD‐10 codes). Propensity score 1:1 greedy nearest neighbor matching was used to create cohorts with matched demographic characteristics and above described comorbid conditions in order to pair cases with controls in analysis and minimize confounders. Matching was deemed successful when the standard difference between cohorts was less than 0.05 for all covariates. Comparative rates of minor and major ESS postoperative complications at 3 months after ESS were depicted via risk ratios (RRs), which were calculated using Poisson regression analysis. Both recent and distant infections were analyzed. Finally, a secondary analysis was conducted to determine the relative risk of reoperation in patients with postoperative epistaxis with or without recent COVID‐19 infection (CPT 31241, 30920). Advanced analytics conducted in TriNetX, including descriptive statistics and regression models, were utilized for all analyses [20]. Results Patient Clinical and Demographic Factors Before matching, 10,837 patients with recent COVID‐19 infection and 33,966 patients without recent COVID‐19 infection were present in our cohort (Table 1). The majority of patients from both groups were White and not Hispanic or Latino. Essential (primary) hypertension was the most common comorbidity observed in both cohorts, but was more prevalent in patients with recent infection (p < 0.001). Prior to matching, all comorbid conditions were more commonly observed in patients with recent COVID‐19 infection compared to patients without recent infection (p < 0.05 for all). After successful matching, each cohort contained 10,803 patients with no significant clinical or demographic differences between cohorts. Similarly, all comorbid conditions were more commonly observed in patients with distant COVID‐19 infection compared to patients without recent or distant infection prior to matching (Table 2). After matching, cohorts included for analysis of recent infection contained 10,803 patients, and 3804 patients for analysis of distant infection, with no significant clinical or demographic differences identified. TABLE 1Patient demographics and comorbidities of recent and no recent COVID‐19 infection cohorts before and after propensity score matching.No. (%) or mean (SD)Before matchingAfter matchingRecent COVID‐19No Recent COVID‐19 p SDRecent COVID‐19No Recent COVID‐19 p SDPatients, no.10,83733,96610,80310,803DemographicsAge at index49.7 (16.9)50.8 (17.2)< 0.0010.06549.7 (16.9)49.6 (17.0)0.6180.007Male5269 (48.6)16,858 (49.6)0.0670.025251 (48.6)5227 (48.4)0.7440.004Female5296 (48.9)16,332 (48.1)0.1540.0165282 (48.9)5302 (49.1)0.7850.004White7913 (73.0)25,006 (73.6)0.2160.0147892 (73.1)7944 (73.5)0.4240.011Black or African American927 (8.6)2685 (7.9)0.0310.024923 (8.5)874 (8.1)0.2270.016Asian539 (5.0)1451 (4.3)0.0020.033536 (5.0)531 (4.9)0.8750.002American Indian or Alaska Native72 (0.7)151 (0.4)0.0050.0371 (0.7)64 (0.6)0.5460.008Native Hawaiian or Other Pacific Islander61 (0.6)137 (0.4)0.0290.02360 (0.6)50 (0.5)0.3390.013Unknown Race960 (8.9)3329 (9.8)0.0040.032957 (8.9)950 (8.8)0.8670.002Other Race365 (3.4)1207 (3.6)0.3610.01364 (3.4)390 (3.6)0.3350.013Hispanic or Latino958 (8.8)2254 (6.6)< 0.0010.083953 (8.8)996 (9.2)0.3070.014Not Hispanic or Latino7803 (72.0)23,712 (69.8)< 0.0010.0487778 (72.0)7841 (72.6)0.3380.013Unknown Ethnicity2076 (19.2)8000 (23.6)< 0.0010.1072072 (19.2)1966 (18.2)0.0640.025DiagnosisDiabetes mellitus due to underlying condition155 (1.4)349 (1.0)0.0010.037131 (1.2)120 (1.1)0.4850.01Drug or chemical induced diabetes mellitus98 (0.9)213 (0.6)0.0020.03283 (0.8)78 (0.7)0.6920.005Type 1 diabetes mellitus172 (1.6)439 (1.3)0.0210.025156 (1.4)135 (1.2)0.2150.017Type 2 diabetes mellitus1440 (13.3)3948 (11.6)< 0.0010.051410 (13.1)1250 (11.6)0.0010.045Other specified diabetes mellitus150 (1.4)354 (1.0)0.0030.031131 (1.2)123 (1.1)0.6140.007Chronic obstructive pulmonary disease, unspecified702 (6.5)1653 (4.9)< 0.0010.07689 (6.4)646 (6.0)0.2240.017Obesity, unspecified2000 (18.5)4975 (14.6)< 0.0010.1031986 (18.4)1903 (17.6)0.1420.02Essential (primary) hypertension3769 (34.8)10,448 (30.8)< 0.0010.0863739 (34.6)3658 (33.9)0.2460.016Nicotine dependence926 (8.5)2130 (6.3)< 0.0010.088918 (8.5)893 (8.3)0.5390.008Abbreviation: SD = standard difference. Patient demographics and comorbidities of recent and no recent COVID‐19 infection cohorts before and after propensity score matching. Abbreviation: SD = standard difference. TABLE 2Patient demographics and comorbidities of distant and no recent or distant COVID‐19 infection cohorts before and after propensity score matching.No. (%) or mean (SD)Before matchingAfter matchingDistant COVID‐19No recent or distant COVID‐19 p SDDistant COVID‐19No recent or distant COVID‐19 p SDPatients, no.382730,72638043804DemographicsAge at index50.8 (16.7)50.7 (17.3)0.8110.00450.8 (16.8)50.8 (16.9)0.5480.014Male1755 (45.9)15,470 (50.3)< 0.0010.091743 (45.8)1707 (44.9)0.4070.019Female1973 (51.6)14,562 (47.4)< 0.0010.0831963 (51.6)1991 (52.3)0.5210.015White2840 (74.2)22,530 (73.3)0.2430.022826 (74.3)2844 (74.8)0.6360.011Black or African American348 (9.1)2404 (7.8)0.0060.046346 (9.1)335 (8.8)0.6590.01Asian152 (4.0)1329 (4.3)0.3090.018150 (3.9)149 (3.9)0.9530.001American Indian or Alaska Native23 (0.6)136 (0.4)0.1720.02223 (0.6)18 (0.5)0.4340.018Native Hawaiian or Other Pacific Islander33 (0.9)117 (0.4)< 0.0010.06131 (0.8)34 (0.9)0.7090.009Unknown Race291 (7.6)3117 (10.1)< 0.0010.089288 (7.6)269 (7.1)0.4030.019Other Race140 (3.7)1093 (3.6)0.7510.005140 (3.7)155 (4.1)0.3730.02Hispanic or Latino321 (8.4)2007 (6.5)< 0.0010.071320 (8.4)344 (9.0)0.330.022Not Hispanic or Latino2721 (71.1)21,396 (69.6)0.0630.0322701 (71.0)2728 (71.7)0.4940.016Unknown Ethnicity785 (20.5)7323 (23.8)< 0.0010.08783 (20.6)732 (19.2)0.1430.034DiagnosisDiabetes mellitus due to underlying condition85 (2.2)273 (0.9)< 0.0010.10873 (1.9)66 (1.7)0.5490.014Drug or chemical induced diabetes mellitus49 (1.3)172 (0.6)< 0.0010.07643 (1.1)36 (0.9)0.4290.018Type 1 diabetes mellitus94 (2.5)373 (1.2)< 0.0010.09384 (2.2)69 (1.8)0.2210.028Type 2 diabetes mellitus654 (17.1)3333 (10.8)< 0.0010.181633 (16.6)567 (14.9)0.0380.048Other specified diabetes mellitus98 (2.6)286 (0.9)< 0.0010.12579 (2.1)60 (1.6)0.1040.037Chronic obstructive pulmonary disease, unspecified340 (8.9)1357 (4.4)< 0.0010.18333 (8.8)297 (7.8)0.1340.034Obesity, unspecified921 (24.4)4075 (13.3)< 0.0010.28907 (23.8)915 (24.1)0.830.005Essential (primary) hypertension1664 (43.5)8946 (29.1)< 0.0010.3021643 (43.2)1673 (44.0)0.4880.016Nicotine dependence419 (10.9)1786 (5.8)< 0.0010.186417 (11.0)433 (11.4)0.560.013Abbreviation: SD = standard difference. Patient demographics and comorbidities of distant and no recent or distant COVID‐19 infection cohorts before and after propensity score matching. Abbreviation: SD = standard difference. Relative Risk of Post‐Operative Complications Among Patients With Recent COVID‐19 Infection The overall risk of overall minor complications within 3 months of ESS was significantly higher in patients with recent COVID‐19 infection (4.4%) compared to patients without recent infection (3.5%) (RR: 1.264, 95% CI: [1.081, 1.476]) (Table 3). Epistaxis was the most common postoperative complication for both patients with (2.7%) and without (2.1%) recent infection, but was more frequent in patients with recent infection (RR: 1.236, 95% CI: [1.036, 1.474]). Patients with recent infection were also at greater risk for postoperative nasal congestion (2.1%) compared to patients without recent infection (1.7%) (RR: 1.273, 95% CI: [1.016, 1.596]). This increased nasal congestion persisted in patients with recent COVID‐19 infection at 6 months to 1 year after ESS (RR: 1.327, 95% CI: [1.083, 1.625]). Risks of all other minor complications were 1% or lower for both cohorts. Very few patients experienced major complications from either cohort, with a risk of 1.1% and 0.9% for patients with and without recent infection, respectively. The risks of each individual major complication were 0.4% or less for both cohorts, with no significant differences identified between the two groups. Inpatient stays were only required for 1.8% and 1.6% of patients with and without recent infection within 3 months of ESS. TABLE 3Postoperative complication risks in patients with and without recent COVID‐19 infection.ComplicationComplication risk, no. (%)RR95% CIRecent COVID infection (n = 10,803)No recent COVID infection (n = 10,803)Minor complicationsOverall311 (4.3)287 (3.8)1.129(0.959, 1.33)Abscess103 (1.1)91 (1.0)1.163(0.879, 1.540)Epistaxis269 (2.7)219 (2.1)1.236(1.036, 1.474)Orbital hematoma10 (0.1)10 (0.1)1(0.416, 2.402)Surgical infection13 (0.1)10 (0.1)1.298(0.570, 2.960)Anosmia27 (0.3)21 (0.2)1.19(0.683, 2.074)Nasal congestion165 (2.1)134 (1.7)1.273(1.016, 1.596)Ecchymosis13 (0.1)15 (0.1)0.869(0.413, 1.824)Major complicationsOverall96 (1.2)94 (1.2)1.032(0.776, 1.374)Orbital injury13 (0.1)10 (0.1)1.302(0.571, 2.968)CSF leak17 (0.2)10 (0.1)1.705(0.781, 3.723)Pneumonia43 (0.4)40 (0.4)1.091(0.710, 1.676)Ventilator dependence10 (0.1)10 (0.1)1(0.416, 2.402)Deep vein thrombosis15 (0.1)13 (0.1)1.152(0.548, 2.419)Pulmonary embolism10 (0.1)10 (0.1)1.001(0.417, 2.405)Stroke17 (0.2)12 (0.1)1.421(0.679, 2.974)Acute MI14 (0.1)12 (0.1)1.167(0.540, 2.521)Sepsis28 (0.3)20 (0.2)1.406(0.793, 2.495)Other VTE23 (0.2)29 (0.3)0.794(0.460, 1.371)Death17 (0.2)14 (0.1)1.208(0.596, 2.450)Other complications37 (0.4)26 (0.2)1.423(0.862, 2.347)Healthcare utilizationInpatient encounters133 (1.8)121 (1.6)1.103(0.864, 1.408)Abbreviations: 95% CI = 95% confidence interval; CSF = cerebrospinal fluid; MI = myocardial infarction; RR = risk ratio; VTE = venous thromboembolism. Postoperative complication risks in patients with and without recent COVID‐19 infection. Abbreviations: 95% CI = 95% confidence interval; CSF = cerebrospinal fluid; MI = myocardial infarction; RR = risk ratio; VTE = venous thromboembolism. Given the increased rates of epistaxis in patients with recent COVID‐19 infection, we sought to evaluate whether patients also experience increased rates of severe epistaxis requiring control in the operating room (OR). We found that patients with postoperative epistaxis with or without recent COVID‐19 infection had similar risk for requiring operative intervention in the OR (2.5% and 3.6%, respectively). However, patients with recent COVID‐19 infection and postoperative epistaxis were more likely to utilize emergency department services within 3 months of ESS compared to patients without recent infection and postoperative epistaxis (39.3% vs. 27.6%; RR: 1.422, 95% CI: [1.200, 1.685]). Relative Risk of Post‐Operative Complications Among Patients With Distant COVID‐19 Infection Overall risk of minor complications was not significantly different between patients with distant COVID infection (4.7%) and patients without COVID infection (3.9%; RR: 1.224, 95% CI: [0.948, 1.579]; Table 4). The overall risk of minor complications within 3 months of ESS was 4.7% for patients with distant infection and 3.9% for patients without infection (Table 4). Major complications overall were rare for both cohorts, with a risk of 1.3% for patients with distant infection and 1.0% for patients with no recent or distant infection (RR: 1.324, 95% CI: [0.820, 2.138]). The risk of each individual major complication was less than 0.5% for both cohorts. Inpatient stays were only required for 2.1% and 1.6% of patients with and without distant infection within 3 months of ESS (RR: 1.336, 95% CI: [0.880, 2.029]). TABLE 4Postoperative complication risks in patients with and without distant COVID‐19 infection.ComplicationComplication risk, no. (%)RR95% CIDistant COVID infection (n = 3804)No distant or recent COVID infection (n = 3804)Minor complicationsOverall126 (4.8)110 (3.8)1.250(0.962, 1.623)Abscess36 (1.1)32 (1.0)1.166(0.726, 1.872)Epistaxis87 (2.5)85 (2.4)1.043(0.776, 1.401)Orbital hematoma10 (0.3)0NANASurgical infection10 (0.3)10 (0.3)1.004(0.418, 2.410)Anosmia10 (0.3)11 (0.3)0.919(0.391, 2.162)Nasal congestion56 (2.2)47 (1.7)1.309(0.892, 1.922)Ecchymosis10 (0.3)10 (0.3)1.007(0.420, 2.418)Major complicationsOverall41 (1.5)33 (1.1)1.375(0.867, 2.181)Orbital injury10 (0.3)10 (0.3)1.007(0.420, 2.417)CSF leak10 (0.3)10 (0.3)0.999(0.416, 2.397)Pneumonia16 (0.5)16 (0.5)1.059(0.530, 2.114)Ventilator dependence10 (0.3)10 (0.3)0.999(0.416, 2.398)Deep vein thrombosis10 (0.3)10 (0.3)1.004(0.418, 2.409)Pulmonary embolism10 (0.3)10 (0.3)1.005(0.419, 2.412)Stroke10 (0.3)10 (0.3)1.008(0.420, 2.419)Acute MI10 (0.3)10 (0.3)1.008(0.420, 2.420)Sepsis11 (0.3)10 (0.3)1.112(0.473, 2.615)Other VTE11 (0.3)10 (0.3)1.11(0.472, 2.610)Death10 (0.3)10 (0.3)1.003(0.418, 2.409)Other complications16 (0.4)10 (0.3)1.614(0.733, 3.551)Healthcare utilizationInpatient encounters47 (2.1)40 (1.6)1.336(0.880, 2.029)Abbreviations: 95% CI = 95% confidence interval; CSF = cerebrospinal fluid; MI = myocardial infarction; RR = risk ratio; VTE = venous thromboembolism. Postoperative complication risks in patients with and without distant COVID‐19 infection. Abbreviations: 95% CI = 95% confidence interval; CSF = cerebrospinal fluid; MI = myocardial infarction; RR = risk ratio; VTE = venous thromboembolism. Discussion This study analyzes nationwide population‐level data to compare risks of postoperative complications of ESS in patients with CRS with and without recent or distant COVID‐19 infection. COVID‐19 infection increased the risk of postoperative epistaxis and nasal congestion. However, the risk of major and life‐threatening complications remains rare for all patient cohorts, with no differences identified associated with recent or distant COVID‐19 infection. The overall risks of minor complications remain low in the setting of recent COVID‐19 infection, emphasizing the efficacy of ESS for CRS. Patients with a prior diagnosis of nasal congestion were excluded from analysis in order to best capture new postoperative symptoms. As nasal obstruction is a cardinal symptom of CRS, it is likely patients analyzed still experienced some degree of uncoded nasal congestion prior to ESS [21]. Recent COVID‐19 infection likely contributed to worsening symptoms of nasal obstruction and congestion, both prior to surgery and also in the postoperative time period. Epistaxis was the most common complication observed for all cohorts of patients included in the analysis of this study. ESS is a highly advantageous surgical option for patients with CRS due to its high accuracy and overall low complication rates. However, epistaxis, either early or delayed postoperatively, is a well‐characterized complication of ESS [22, 23]. We controlled for potential risk factors for epistaxis including hypertension and other patient comorbidities using PSM [24, 25]. Use of medications associated with epistaxis, such as anticoagulants, was not investigated in this study due to limitations of the medication data. The SARS‐CoV‐2 virus has potential to invade vascular endothelial cells, and epistaxis has been identified in prior studies as a potential presenting symptom in patients with COVID‐19 infection [26, 27]. Changes in the fragility of the nasal vasculature in patients with recent COVID‐19 infection thus may predispose these patients to epistaxis after ESS. Our results show that patients with recent infection have similar rates of return to the OR for severe epistaxis requiring control of nasal hemorrhage and/or endoscopic arterial ligation compared to patients without recent infection. While rates of reoperation are similar, patients with recent COVID‐19 infection and postoperative epistaxis after ESS were more likely to utilize emergency department services compared to patients without recent infection and postoperative epistaxis, indicating that even non‐OR‐level hemorrhage may contribute meaningfully to post‐ESS morbidity and unplanned care. Accordingly, even in the context of generally minor complications, heightened vigilance and patient counseling are warranted for individuals with recent COVID‐19 infection due to their increased risk of postoperative epistaxis. Major complications were extremely rare for all cohorts of patients included in this study, with no increased risk of any major complications identified for patients with recent or distant COVID‐19 infection. Prior studies have similarly found that rates of major complications, such as injury to the skull base and orbits, and mortality rates are low after ESS for CRS [28]. The results of our study are consistent with rates of complications identified in this prior work. Our recent study by Wei et al. investigating the impact of recent COVID‐19 infection on complications of septorhinoplasty and other nasal surgery found that there was no increased risk for complications in patients with recent infection [18]. This study thus supports the safety of sinus surgery in patients recovered from COVID‐19 infection as recent as 2 months prior to surgery, even in the context of possibly resolving nasal inflammation. Inpatient stays were infrequent for all cohorts of patients included in this study. This finding was expected given the exclusion of patients with severe indications for ESS that may necessitate admission (e.g., intracranial abscess, invasive fungal sinusitis, etc.) in order to reduce confounding factors influencing postoperative complications. It is likely that the inpatient stays identified in this study can be at least partially attributed to other patient comorbid conditions that may require their hospitalization rather than due to direct complications of ESS. The value of this study lies in the use of population‐wide data and the ability to include large cohorts of patients. The propensity score matching algorithm of the TriNetX database permits the creation of equally sized cohorts with confounders minimized and allows for accurate evaluation of the impacts of COVID‐19 on ESS complications. Ultimately, this data is highly applicable to patients with CRS undergoing ESS in the United States. This study has limitations. While ICD‐10 codes for CRS and CPT codes for ESS are largely universal in electronic health records (EHR), documentation of postoperative complications may be variably documented between institutions. Despite the use of PSM to control for a plethora of relevant demographic and clinical characteristics, complete elimination of confounders is not possible. Patients with severe comorbid conditions were still included in the analysis for all cohorts, which thus may impact the increased risk of complications. Individuals with recent COVID‐19 infection may also be more likely to be closely monitored in the postoperative period, thus may have improved follow‐up and charting of post‐operative conditions and complications. Propensity score matching also does not account for various variables that could not be queried in TriNetX, such as patient socioeconomic status, COVID‐19 vaccination status, COVID‐19 severity, or surgeon‐specific factors. The inability to account for vaccination status, COVID‐19 reinfection, or specific viral variants is an additional limitation as these factors may influence both perioperative risk and recovery trajectory. In addition, the exclusion of patients with urgent and emergent indications for ESS may introduce selection bias, favoring healthier or more stable patients in the recent infection cohort. Thus, the presence or absence of recent COVID‐19 infection should be contextualized with other patient‐specific risk factors when determining whether to continue with ESS soon after infection. Further studies are warranted to investigate the effects of COVID‐19 vaccination and disease severity in CRS patients undergoing ESS. Conclusions This study emphasizes the safety of endoscopic sinus surgery for chronic rhinosinusitis in patients recently recovered from COVID‐19 infection. While recovering patients may be at modestly increased risk for minor complications such as epistaxis, major complications remain infrequent and without significant difference to major complication rates in patients without COVID‐19 in the past year. These results emphasize the importance of considering the timing of COVID‐19 infection along with other patient‐specific clinical factors when evaluating surgical risk and postoperative care needs for ESS patients. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Appendix S1: Supporting Information. Acknowledgments The authors have nothing to report. Jackert E. P., Ayo‐Ajibola O., and Wei E. X., “Assessing the Safety of Endoscopic Sinus Surgery After COVID‐19 Infection,” Laryngoscope Investigative Otolaryngology 10, no. 6 (2025): e70326, 10.1002/lio2.70326. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Appendix S1: Supporting Information. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.